Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply
| Main Authors: | , , |
|---|---|
| Format: | Journal Article |
| Published: |
The Lancet Publishing Group
2016
|
| Online Access: | http://hdl.handle.net/20.500.11937/36236 |